ProBiotix Health Management
Management criteria checks 1/4
We currently do not have sufficient information about the CEO.
Key information
Steen Andersen
Chief executive officer
UK£250.7k
Total compensation
| CEO salary percentage | 94.9% |
| CEO tenure | 1.8yrs |
| CEO ownership | n/a |
| Management average tenure | less than a year |
| Board average tenure | 2.7yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -UK£496k |
| Mar 31 2024 | n/a | n/a | -UK£621k |
| Dec 31 2023 | UK£251k | UK£238k | -UK£747k |
Compensation vs Market: Steen's total compensation ($USD314.84K) is below average for companies of similar size in the German market ($USD472.15K).
Compensation vs Earnings: Insufficient data to compare Steen's compensation with company performance.
CEO
Steen Andersen (61 yo)
1.8yrs
Tenure
UK£250,714
Compensation
Mr. Steen Dannemann Andersen is Chief Executive Officer and Director of ProBiotix Limited from January 01, 2023. He was Chief Executive Officer of Bifodan A/S. He was Chief Executive Officer of Fluxome Sci...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 1.8yrs | UK£250.71k | no data | |
| Head of Marketing | less than a year | no data | no data | |
| Secretary | less than a year | no data | no data |
0.6yrs
Average Tenure
Experienced Management: X90's management team is not considered experienced ( 0.6 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 1.8yrs | UK£250.71k | no data | |
| Non-Executive Chairman | 2.7yrs | UK£30.00k | 0.090% € 8.6k | |
| Board Director | 6.6yrs | UK£55.00k | 3.88% € 367.5k | |
| Director | less than a year | no data | no data | |
| Non-Executive Director | 2.7yrs | UK£20.00k | no data |
2.7yrs
Average Tenure
61yo
Average Age
Experienced Board: X90's board of directors are not considered experienced ( 2.7 years average tenure), which suggests a new board.